Protease‑Resilient Intranasal Biologics: NRB‑1A In Silico Framework for Five‑Minute Migraine Intervention
Abstract
BackgroundMigraine pain escalates through rapid activation of calcitonin gene–related peptide signaling within trigeminal pathways, driving vasodilation, neurogenic inflammation, and nociceptor sensitization that can amplify within minutes of attack onset (Edvinsson, 2015; Goadsby et al., 2017). The superior nasal compartments, including the superior turbinates’ and olfactory cleft, are closely opposed to olfactory epithelium and trigeminal nerve endings, creating a short diffusional path for locally acting biologics to intercept CGRP or its receptor near the origin of pain signaling (Illum, 2003; Djupesland, 2013; Thorne, Pronk, Padmanabhan, & Frey, 2004). This route must overcome nasal physiology constraints such as mucociliary clearance and protease activity that can reduce residence time and degrade proteins, making compact, high affinity, fast on rate antagonists biologically attractive for minute scale action (Illum, 2003; Wang, 2005; von Mentzer et al., 2020). ObjectiveEvaluate, in silico only, whether intranasal delivery of a preformed, humanized, Fc‑less nanobody or single chain variable fragment in the 12 to 30 kDa range can achieve biologically plausible and clinically meaningful CGRP axis inhibition within five minutes, sustain several hours of localized suppression governed by nasal physiology and target kinetics, and return toward baseline within 24 to 48 hours. Additionally, parameterize a short duration adeno associated virus secretion fallback that extends…
How strong is the evidence?
Evidence Hub reads this as a preprint, done in computer models (in silico), not in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health. Reported size: 35,000 participants or records.
Read the paper
Related studies
- Calcium Ions in the Physiology and Pathology of the Central Nervous System
- AI-powered in silico twins: redefining precision medicine through simulation, personalization, and predictive healthcare
- In silico functional, structural and pathogenicity analysis of missense single nucleotide polymorphisms in human MCM6 gene
- In Silico drug repurposing pipeline using deep learning and structure based approaches in epilepsy
- Targeting serotonin receptors with phytochemicals – an in-silico study
- In silico exploration of anti-prostate cancer compounds from differential expressed genes
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.